Related Experiment Videos
Options for modulation of drug resistance in ovarian cancer
H. J. G. Arts1, A. G. J. Van Der Zee, S. De Jong
1Departments of Gynaecological Oncology and Medical Oncology, University Hospital Groningen, The Netherlands.
Abstract:
The objective of this paper is to present an update of mechanisms responsible for drug resistance in ovarian cancer and the possible therapeutic options to modulate this resistance using literature review with emphasis on data acquired in studies comprising ovarian tumor samples. The classic concepts on resistance in ovarian cancer, namely platinum and multidrug resistance, are briefly discussed, followed by a description of more recent insights concerning the role of apoptosis in the development of chemoresistance. A wide variety of mechanisms may be responsible for drug resistance in ovarian cancer. However, a growing body of evidence indicates that defects in the intra- and extracellular apoptotic pathways are an important cause of resistance to cytotoxic agents which opens several new treatment strategies.
Insights
Drug resistance in ovarian cancer is complex, involving traditional mechanisms and new insights into apoptosis defects. Understanding these pathways offers novel therapeutic strategies for overcoming chemoresistance.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Ovarian cancer frequently develops resistance to chemotherapy, limiting treatment efficacy.
- Classic resistance mechanisms include platinum resistance and multidrug resistance (MDR).
- Emerging evidence highlights the role of apoptosis dysregulation in chemoresistance.
Purpose of the Study:
- To provide an updated review of drug resistance mechanisms in ovarian cancer.
- To explore therapeutic strategies targeting resistance pathways.
- To emphasize data from studies on ovarian tumor samples.
Main Methods:
- Comprehensive literature review.
- Analysis of studies focusing on ovarian cancer.
- Synthesis of data on resistance mechanisms and therapeutic options.
Main Results:
- Drug resistance in ovarian cancer involves diverse mechanisms.
- Defects in intracellular and extracellular apoptotic pathways are significant contributors to chemoresistance.
- Apoptosis modulation presents promising avenues for new treatments.
Conclusions:
- Dysregulation of apoptosis is a key factor in ovarian cancer drug resistance.
- Targeting apoptotic pathways offers potential for overcoming chemoresistance.
- Further research into these mechanisms can guide novel therapeutic development.